Literature DB >> 17298289

Blocking sodium channels to treat neuropathic pain.

Birgit T Priest1, Gregory J Kaczorowski.   

Abstract

Neuropathic pain remains a large unmet medical need. A number of therapeutic options exist, but efficacy and tolerability are less than satisfactory. Based on animal models and limited data from human patients, the pain and hypersensitivity that characterize neuropathic pain are associated with spontaneous discharges of normally quiescent nociceptors. Sodium channel blockers inhibit this spontaneous activity, reverse nerve injury-induced pain behavior in animals and alleviate neuropathic pain in humans. Several sodium channel subtypes are expressed primarily in sensory neurons and may contribute to the efficacy of sodium channel blockers. In this report, the authors review the current understanding of the role of sodium channels and of specific sodium channel subtypes in neuropathic pain signaling.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17298289     DOI: 10.1517/14728222.11.3.291

Source DB:  PubMed          Journal:  Expert Opin Ther Targets        ISSN: 1472-8222            Impact factor:   6.902


  12 in total

1.  Subtype-selective sodium channel blockers promise a new era of pain research.

Authors:  Birgit T Priest; Gregory J Kaczorowski
Journal:  Proc Natl Acad Sci U S A       Date:  2007-05-08       Impact factor: 11.205

Review 2.  Sodium channel blockers for the treatment of neuropathic pain.

Authors:  Anindya Bhattacharya; Alan D Wickenden; Sandra R Chaplan
Journal:  Neurotherapeutics       Date:  2009-10       Impact factor: 7.620

3.  Endothelin-1 Decreases Excitability of the Dorsal Root Ganglion Neurons via ETB Receptor.

Authors:  Nandkishor K Mule; Jitendra N Singh; Kunal U Shah; Anil Gulati; Shyam S Sharma
Journal:  Mol Neurobiol       Date:  2017-06-16       Impact factor: 5.590

4.  Targeting Neuroimmune Interactions in Diabetic Neuropathy with Nanomedicine.

Authors:  Mihály Balogh; Jelena M Janjic; Andrew J Shepherd
Journal:  Antioxid Redox Signal       Date:  2022-01       Impact factor: 8.401

5.  In vivo and ex vivo inhibition of spinal nerve ligation-induced ectopic activity by sodium channel blockers correlate to in vitro inhibition of NaV1.7 and clinical efficacy: a pharmacokinetic-pharmacodynamic translational approach.

Authors:  Ivana Kalezic; Lei Luo; Per-Eric Lund; Anders B Eriksson; Tjerk Bueters; Sandra A G Visser
Journal:  Pharm Res       Date:  2013-02-01       Impact factor: 4.200

6.  Structurally minimized mu-conotoxin analogues as sodium channel blockers: implications for designing conopeptide-based therapeutics.

Authors:  Tiffany S Han; Min-Min Zhang; Aleksandra Walewska; Pawel Gruszczynski; Charles R Robertson; Thomas E Cheatham; Doju Yoshikami; Baldomero M Olivera; Grzegorz Bulaj
Journal:  ChemMedChem       Date:  2009-03       Impact factor: 3.466

Review 7.  Are voltage-gated sodium channels on the dorsal root ganglion involved in the development of neuropathic pain?

Authors:  Wei Wang; Jianguo Gu; Yun-Qing Li; Yuan-Xiang Tao
Journal:  Mol Pain       Date:  2011-02-23       Impact factor: 3.395

8.  Bioinformatic characterizations and prediction of K+ and Na+ ion channels effector toxins.

Authors:  Rima Soli; Belhassen Kaabi; Mourad Barhoumi; Mohamed El-Ayeb; Najet Srairi-Abid
Journal:  BMC Pharmacol       Date:  2009-03-10

9.  Ion channels as drug targets: the next GPCRs.

Authors:  Gregory J Kaczorowski; Owen B McManus; Birgit T Priest; Maria L Garcia
Journal:  J Gen Physiol       Date:  2008-04-14       Impact factor: 4.086

10.  Inhibition of voltage-gated sodium channels by sumatriptan bioisosteres.

Authors:  Roberta Carbonara; Alessia Carocci; Julien Roussel; Giuseppe Crescenzo; Canio Buonavoglia; Carlo Franchini; Giovanni Lentini; Diana Conte Camerino; Jean-François Desaphy
Journal:  Front Pharmacol       Date:  2015-07-24       Impact factor: 5.810

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.